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Abstract
Background: HIV-1-related inflammation is associated with increased levels of biomarkers of vascular adhesion and
endothelial activation, and may increase production of the inflammatory protein angiopoietin-2 (ANG-2), an adverse
prognostic biomarker in severe systemic infection. We hypothesized that antiretroviral therapy (ART) initiation would
decrease endothelial activation, reducing plasma levels of ANG-2.
Methods: Antiretroviral-naïve Kenyan women with advanced HIV infection were followed prospectively. Endothelial
activation biomarkers including soluble intercellular adhesion molecule-1 (ICAM-1), vascular adhesion molecule-1
(VCAM-1), and E-selectin, and plasma ANG-2 and angiopoietin-1 (ANG-1) were tested in stored plasma samples
from 0, 6, and 12 months after ART initiation. We used Wilcoxon matched-pairs signed rank tests to compare
endothelial activation biomarkers across time-points, generalized estimating equations to analyze associations with
change in log10-transformed biomarkers after ART initiation, and Cox proportional-hazards regression to analyze
associations with mortality.
Results: The 102 HIV-1-seropositive women studied had advanced infection (median CD4 count, 124 cells/μL).
Soluble ICAM-1 and plasma ANG-2 levels decreased at both time-points after ART initiation, with concomitant
increases in the beneficial protein ANG-1. Higher ANG-2 levels after ART initiation were associated with higher
plasma HIV-1 RNA, oral contraceptive pill use, pregnancy, severe malnutrition, and tuberculosis. Baseline ANG-2
levels were higher among five women who died after ART initiation than among women who did not (median
2.85 ng/mL [inter-quartile range (IQR) 2.47–5.74 ng/mL] versus median 1.32 ng/mL [IQR 0.35–2.18 ng/mL], p = 0.01).
Both soluble ICAM-1 and plasma ANG-2 levels predicted mortality after ART initiation.
Conclusions: Biomarkers of endothelial activation decreased after ART initiation in women with advanced HIV-1
infection. Changes in plasma ANG-2 were associated with HIV-1 RNA levels over 12 months of follow-up. Soluble
ICAM-1 and plasma ANG-2 levels represent potential biomarkers for adverse outcomes in advanced HIV-1 infection.
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Background
HIV-1-infected persons are at increased risk not only for
AIDS-defining infections and malignancies, but also for
cardiovascular disease, kidney and liver disease, and
non-AIDS-defining malignancies [1]. Increasing evi-
dence suggests that non-AIDS-defining complications
are associated with chronic activation of inflammatory
and coagulation pathways [2-6]. Because even prolonged
effective antiretroviral therapy (ART) may not normalize
biomarkers of inflammation and coagulation [2], a better
understanding of the relationship between inflammatory
pathways and HIV-1 pathogenesis is needed. In particu-
lar, the pathogenesis of HIV-1-related endothelial activa-
tion merits further investigation [7].
HIV-1-induced inflammation has been linked to in-
creased biomarkers of endothelial activation, including
soluble intercellular adhesion molecule-1 (ICAM-1), vas-
cular adhesion molecule-1 (VCAM-1), and E-selectin
[5,8,9]. HIV-1 induces up-regulation of these cellular ad-
hesion molecules, leading to an increase in their soluble
forms in plasma [5,8,9]. Soluble VCAM-1 and ICAM-1
levels decrease after ART initiation and increase after
treatment interruption [10,11]. Higher levels of soluble
ICAM-1 have been associated with increased mortality
in HIV-1-infected persons [12]. We hypothesized that
the extent of HIV-1-related endothelial activation may
be associated with altered levels of the vascular growth
factors angiopoietin-1 and-2 (ANG-1 and ANG-2), re-
cently identified as important regulators of endothelial
quiescence and activation.
ANG-1 is widely expressed in human endothelial cells,
where it plays a key role in maintaining vascular stability
by binding to Tie-2, a receptor tyrosine kinase [13]. Its
effect is antagonized by ANG-2, which blocks ANG-1
/Tie-2 binding and is up-regulated at sites of vascular in-
jury or local inflammation [13]. ANG-2 sensitizes the
endothelium to tumor necrosis factor alpha (TNF-α),
amplifying its effects and mediating pro-inflammatory
and angiogenic effects that can result in manifestations
of severe systemic infection, including vascular leak and
organ dysfunction [13-15]. While plasma levels of
ANG-1 are high in healthy individuals, plasma levels of
ANG-2 are usually low or undetectable [13-15].
In a study of angiogenic factors and severe bacterial
infection in Malawian children, levels of ANG-2 were
significantly elevated in HIV-1-seropositive children
relative to seronegative children [16]. We hypothesized
that advanced HIV-1 infection would be associated with
endothelial activation (increased ANG-2, decreased
ANG-1) that would resolve, at least partially, after ART
initiation. Our aim was therefore to evaluate ART-
related changes in ANG-1 and ANG-2 after ART initi-
ation. We also examined levels of soluble ICAM-1,
VCAM-1, and E-selectin to confirm that changes in
these biomarkers accompanied changes in ANG-1 and
ANG-2. A secondary aim was to determine the extent to
which angiopoietin levels were associated with HIV-1 RNA
suppression and clinical outcomes in this population.
Methods
Study population and procedures
The study followed HIV-1-seropositive, non-pregnant
Kenyan women who initiated ART in a research clinic in
Mombasa, Kenya between February 2005 and January
2008 [17]. Women enrolled if they were eligible for ART
according to Kenyan National Guidelines during this
period (CD4 count ≤200 cells/ml or AIDS-defining ill-
ness) [18], and willing to undergo scheduled follow-up.
At treatment initiation and monthly thereafter, women
were interviewed using standardized questionnaires
about recent behavior and health status, then underwent
a standardized physical examination. Blood was collected
for HIV-1 quantitation at baseline and quarterly there-
after. A standard first-line ART regimen of stavudine or
zidovudine, lamivudine, and nevirapine was provided, in
accordance with World Health Organization (WHO)
and Kenyan National Guidelines at the time of study
participation [18].
All participants gave written informed consent. Ethi-
cal review committees of the Kenyatta National Hosi-
pital, Kenya Medical Research Institute, University of
Washington, and Fred Hutchinson Cancer Research
Center approved the research protocols.
Laboratory methods
HIV-1 serostatus was evaluated using the Detect HIV1/2
ELISA (BioChem Immunosystems) confirmed by a sec-
ond ELISA (Recombigen, Cambridge Biotech or
Vironostika HIV-1 Uni-Form II Ag/Ab, bioMérieux).
CD4 cell counts were determined using FACS Count
(Becton Dickinson). Pregnancy testing was performed
using a rapid β–human chorionic gonadotropin test
(Plasmatec Laboratory Products). Plasma specimens
were frozen at −70°C until shipment to Seattle on dry
ice or in liquid nitrogen for HIV-1 RNA quantitation
using the Gen-Probe HIV-1 viral load assay [19]. The
lower limit of quantitation was 100 copies/mL.
Aliquots of stored plasma samples were sent to
Toronto on dry ice and stored at −80°C prior to testing
for endothelial activation biomarkers [20,21]. Of note, all
biomarkers tested are stable for ≥24 hours and resistant
to up to four freeze-thaw cycles [22,23]. Plasma concen-
trations (dilution factors indicated in parentheses) of
ANG-1 (1:5), ANG-2 (1:5), soluble ICAM-1 (1:1000),
soluble VCAM-1 (1:2000), and soluble E-selectin (1:50)
were measured by ELISA (R&D Systems Duoset kits,
Minneapolis MN, USA) according to manufacturers’ in-
structions with modifications: (1) assays were performed
Graham et al. BMC Infectious Diseases 2013, 13:263 Page 2 of 11
http://www.biomedcentral.com/1471-2334/13/263
in 50 μL per well; (2) plasma samples were incubated
overnight at 4°C; and (3) ELISAs were developed using
Extravidin®-Alkaline Phosphatase (Sigma-Aldrich Canada
Ltd, Oakville, ON, Canada; 1:1000 dilution, 45-minute
incubation) followed by addition of p-nitrophenyl phos-
phate substrate (Sigma-Aldrich Canada Ltd, Oakville,
ON, Canada) before optical density reading at 405 nm.
Concentrations were interpolated from 4-parameter-fit
standard curves. Background levels were determined
from blank wells included on each plate (assay buffer
added instead of sample), and the subsequent optical
density was subtracted from all samples and standards
prior to analysis. Samples with optical densities below
the lowest detectable standard were assigned the value
of that standard. Lower limits of detection for each assay
were as follows: ANG-1 19.53 pg/mL, ANG-2 27.34 pg/
mL, soluble ICAM-1 3.91 pg/mL, soluble VCAM-1
1.95 pg/mL, and soluble E-selectin 11.72 pg/mL.
Statistical methods
An intent-to-treat analysis was used, as we were inter-
ested in the effect of ART initiation on endothelial acti-
vation biomarker levels and the relationship between
biomarkers levels and treatment outcomes in all women
who started ART. Descriptive statistics were used to
present baseline data. Variables for analysis were catego-
rized at clinically meaningful cut-points, if these existed.
Karnofsky performance score was classified as asymptom-
atic or mild symptoms (90–100), moderate symptoms
(80), or unable to work (<80). Nutritional status was cate-
gorized as adequate (body mass index [BMI] ≥ 18.5), mild
or moderate malnutrition (BMI = 16-18.49), or severe mal-
nutrition (BMI < 16) [24]. CD4 cell count was categorized
as <200, 200–350, or >350 cells/μL. Suppressed plasma
HIV-1 RNA was defined as <100 copies/mL.
Spearman’s rho was used to calculate non-parametric
correlations between endothelial activation biomarkers
and plasma HIV-1 RNA at baseline. Wilcoxon matched-
pairs signed rank tests were used to compare endothelial
activation biomarkers among HIV-1-seropositive women
at baseline to 6 or 12 months after ART initiation. Gen-
eralized estimating equations (GEE) with a logit link, ex-
changeable correlation matrix, and robust standard
errors were used to test for change in detection of
plasma ANG-1 and ANG-2 across time-points.
Because additional modeling required normally distrib-
uted data, plasma HIV-1 RNA and endothelial activation
biomarkers were log10-transformed to approximate nor-
mality. GEE with an identity link were used to analyze
associations with change in log10-transformed plasma
ANG-1 or ANG-2 at months 6 and 12 after ART initi-
ation, adjusting for baseline values. Predictors included
baseline (e.g., age) and time-dependent variables (e.g.,
CD4 count). The final multivariable model retained factors
significant at p < 0.10 in the initial adjusted analysis that
also remained significant in multivariable analysis at
p < 0.10. Virologic suppression and change in plasma
ANG-2 (for the ANG-1 outcome) or change in plasma
ANG-1 (for the ANG-2 outcome) were included a priori
in both models as time-dependent predictors, to evaluate
the relationship with plasma HIV-1 RNA and because
the angiopoietins are competitors at the Tie2 receptor,
respectively.
Wilcoxon rank sum tests were used to compare base-
line plasma levels of endothelial activation biomarkers in
women who did or did not die during follow-up. Cox
proportional hazards regression was used to analyze as-
sociations between endothelial activation biomarkers
and other baseline predictors with all-cause mortality
after ART initiation. For this analysis, participants were
censored at the last visit before loss to follow-up or the
month 12 visit, whichever occurred first. All analyses
used the intent-to-treat principle, including women who
changed or discontinued ART. Data were analyzed using
Stata version 11.2 (StataCorp, College Station, Texas). A
two-sided p value <0.05 was considered significant.
Results
Study population
The 102 participating women had a median age of 36
(interquartile range [IQR] 33–41) and most had ad-
vanced HIV-1 infection (17.6% Stage I, 28.4% Stage II,
43.1% Stage III, and 10.8% Stage IV). Two women had
brief exposure to first-line ART prior to enrollment
(1 day of treatment 1 week before enrollment and 3 days
of treatment 4 months before enrollment). All other
women were treatment-naïve. The median CD4 cell
count was 124 cells/μL (IQR 79–164 cells/μL) and me-
dian plasma HIV-1 RNA was 349,066 copies/mL (IQR
149,106–919,173 copies/mL). Nineteen (18.6%) were be-
ing treated for active tuberculosis, and nine (8.8%) were
undernourished. The median hemoglobin was 10.1 g/dL
(IQR 8.8–11.3 g/dL). Forty-two women (41.2%) reported
drinking from 1 to 40 alcoholic beverages per week,
thirty-four women (33.3%) used some form of hormonal
contraception, and eight women (7.8%) reported smok-
ing from 1 to 10 cigarettes per day.
Overall, these women contributed 94.4 person-years of
follow-up after ART initiation, with 95 women (93.1%)
remaining at month 6 and 90 (88.2%) at month 12. The
median CD4 cell count increased to 236 cells/μL (IQR
159–323 cells/μL) by month 6 and 240 cells/μL (IQR
182–332 cells/μL) by month 12. Plasma HIV-1 RNA was
<100 copies/mL for 72.6% of participants at month 6
and for 54.4% at month 12. By a less stringent criterion,
plasma HIV-1 RNA was <400 copies/mL for 82.1% of
participants at month 6 and for 85.6% at month 12.
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Baseline endothelial activation biomarkers
At baseline, there were significant correlations between
several endothelial activation biomarkers and plasma
HIV-1 RNA levels: soluble ICAM (ρ = 0.28, p = 0.005),
E-selectin (ρ = 0.22, p = 0.02), and VCAM-1 (ρ = 0.32,
p = 0.001). The correlation between plasma ANG-2 and
plasma HIV-1 RNA was not significant (ρ = 0.19,
p = 0.06), but plasma ANG-2 was positively correlated
with soluble ICAM (ρ = 0.33, p < 0.001), E-selectin
(ρ = 0.32, p < 0.001), and VCAM-1 (ρ = 0.32, p = 0.001).
There were no significant correlations between plasma
ANG-1 and other endothelial activation biomarkers or
plasma HIV-1 RNA. None of the biomarkers tested corre-
lated with the pre-treatment nadir or baseline CD4 count.
Changes in endothelial activation biomarkers after ART
initiation
Table 1 presents median values for plasma HIV-1 RNA
and endothelial activation biomarkers at each time-point,
with significant differences indicated. As expected, plasma
HIV-1 RNA decreased after ART initiation. Comparing
month 6 and month 12 to baseline levels, plasma ANG-1
increased (p < 0.001 for month 6, p = 0.006 for month 12,
Figure 1A), while plasma ANG-2 decreased at both time-
points (p = 0.01 for month 6, p = 0.03 for month 12,
Figure 1B). This resulted in a highly significant decrease of
the ANG-2:ANG-1 ratio at both time-points (p < 0.001 for
month 6, p = 0.002 for month 12, Figure 1C). In addition,
levels of soluble ICAM-1 decreased at both 6 and
12 months after ART initiation (p < 0.001 for both time-
points). While soluble E-selectin levels were lower at
month 6 than at baseline, they were no different than
baseline at month 12. In contrast, soluble VCAM-1 levels
were not different at month 6, but decreased at month 12.
Plasma ANG-2 levels were detectable in 84.3% of partici-
pants at baseline, 81.0% at month 6, and 68.9% at month
12 (p = 0.008 for difference across time-points).
Predictors of change in log10-transformed plasma ANG-1
and ANG-2 after ART initiation
Mean log10-transformed plasma ANG-1 was 1.13 (stand-
ard deviation [SD] 0.21) at baseline and 1.20 (SD 0.22) at
month 12, for an overall mean change of 0.07 (SD 0.25).
The geometric mean change in plasma ANG-1 at month
12 was an increase of 1.16 ng/mL (SD 1.79 ng/mL). One
participant had undetectable plasma ANG-1 at month 6,
a result several standard deviations below the log10-
transformed mean and all other log10-transformed
ANG-1 values; data from this visit were excluded from
GEE analysis. After adjustment for baseline ANG-1,
change in plasma ANG-1 after ART initiation was asso-
ciated at p < 0.10 with hormonal status, nutritional sta-
tus, Karnofsky performance category, WHO stage, and
CD4 category at baseline, and with hormonal status and
nutritional status during follow-up (Table 2). In multivar-
iable modeling, higher plasma ANG-1 levels after ART
initiation were associated with baseline Karnofsky score
<80 and with HIV-1 RNA suppression and higher plasma
ANG-2 levels during follow-up. Plasma ANG-1 levels
were lower among women who were severely malnour-
ished at baseline and those who became pregnant during
follow-up. There were no associations between change in
log10-transformed plasma ANG-1 and pre-treatment nadir
or baseline CD4 count as a continuous predictor.
Mean log10-transformed plasma ANG-2 was −0.11
(SD 0.72) at baseline and −0.42 (SD 0.89) at month 12,
for a mean change of −0.25 (SD 1.04). The geometric
mean change at month 12 was a decrease of 0.56 ng/mL
(SD 10.91 ng/mL). Table 3 presents the GEE analysis of
factors associated with change in log10 plasma ANG-2
after ART initiation. After adjustment for baseline ANG-
2, change in plasma ANG-2 was associated at p < 0.10
with hormonal status, nutritional status, WHO stage,
and CD4 category at baseline, and with plasma ANG-1
(or change in ANG-l), plasma HIV-1 RNA (or change in
Table 1 Comparison between baseline and 6 or 12 months after ART initiation
Variable Baseline to month 6 comparison a Baseline to month 12 comparison a,b
Baseline median (IQR) Month 6 median (IQR) P value Month 12 median (IQR) P value
Plasma HIV-1 RNA (copies/mL) 349,066 (149,106–919,173) <100 (<100–154) <0.001 <100 (<100–176) <0.001
CD4 Cell count (cells/μL) 124 (79–164) 236 (159–323) <0.001 240 (182–332) <0.001
Angiopoietin-1 (ng/mL) 13.7 (10.2–19.1) 22.5 (16.1–30.2) <0.001 15.8 (11.6–21.9) 0.006
Angiopoietin-2 (ng/mL) 1.50 (0.37–2.43) 0.86 (0.31–1.92) 0.012 0.70 (<0.03–1.59) 0.030
ANG-2/ANG-1 ratio 0.09 (0.02–0.18) 0.03 (0.01–0.08) <0.001 0.03 (0.003–0.11) 0.002
Soluble ICAM-1 (ng/mL) 397.9 (338.0–489.7) 220.5 (185.2–292.5) <0.001 255.2 (200.0–312.5) <0.001
E-Selectin (ng/mL) 24.2 (16.6–32.3) 13.7 (7.4–20.0) <0.001 25.2 (18.5–30.4) 0.29
VCAM-1 (ng/mL) 763.8 (524.3–1107.6) 762.5 (537.0–1,013.3) 0.63 497.8 (407.2–628.6) <0.001
ART antiretroviral therapy, IQR interquartile range.
a Although 90 women completed the study at month 12, there was insufficient sample from one woman for testing of endothelial markers at this time-point.
Therefore, there were 95 paired samples for the baseline to month 6 comparison and 89 paired samples for the baseline to month 12 comparison for all variables
presented above except plasma HIV-1 RNA (90 paired samples available).
b Differences between angiopoietin-1, E-selectin, and VCAM-1 levels between month 6 and month 12 were all significant at p < 0.001.
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RNA), hormonal status, nutritional status, tuberculosis,
and CD4 category during follow-up. In multivariable
modeling, higher plasma ANG-2 was associated with use
of oral contraceptive pills at baseline, and higher plasma
ANG-1, pregnancy, severe malnutrition, and tubercu-
losis during follow-up. Lower plasma ANG-2 levels after
ART initiation were associated with Stage IV disease at
baseline and mild to moderate malnutrition during
follow-up. Although virologic suppression was associated
with somewhat lower plasma ANG-2 levels, this finding
was not significant (mean difference −0.18 log10 with vi-
rologic suppression, p = 0.07). If plasma HIV-1 RNA was
substituted for virologic suppression in this model,
higher plasma HIV-1 RNA was associated with higher
plasma ANG-2 levels (mean difference 0.13 log10 with
each increase in log10 plasma HIV-1 RNA, p = 0.01) and
other findings were very similar (Multivariable Model 2).
There were no associations between change in log10-
transformed plasma ANG-2 and pre-treatment nadir or
baseline CD4 count as a continuous predictor.
Mortality after ART initiation
Five women died during follow-up, for a mortality rate
of 5.3 per 100 (95% confidence interval [CI] 2.2–12.7)
person-years of observation. The deaths occurred from
78 to 313 days after ART initiation. All five deaths oc-
curred during hospitalizations for acute illness, but the
precise cause of death was unknown and autopsies were
not performed. All women who died had adequate nutri-
tional status at baseline by BMI criteria, and WHO stage
varied (one stage I, one stage II, two stage III with tuber-
culosis, and one stage IV with Kaposi’s sarcoma). Four of
these women had CD4 counts <100 cells/μL, and four
had hemoglobin values <9.0 g/dL; all met at least one of
these criteria.
Predictors of mortality
There were no significant differences in plasma levels of
soluble ICAM, VCAM, or E-selectin between women
who died and those who did not (p = 0.07, p = 0.27,
p = 0.27, respectively). Although baseline plasma ANG-1
levels were not significantly different (median 9.85 ng/
mL [IQR 9.14–16.76] versus median 13.80 ng/mL [IQR
10.56–19.12 ng/mL, p = 0.46), baseline plasma ANG-2
levels were significantly higher among women who died
after ART initiation than among women who did not
(median 2.85 ng/mL [IQR 2.47–5.74 ng/mL] versus me-
dian 1.32 ng/mL [IQR 0.35–2.18 ng/mL], p = 0.01). In
addition, the ANG-2:ANG-1 ratio was higher among
women who died than among women who did not (me-
dian 0.27 [IQR 0.27–0.29] versus median 0.08 [IQR
0.02–0.16], p = 0.005). All five women who died were in
the top quartile of ANG-2:ANG-1 ratio values.
Table 4 presents the Cox proportional hazards regres-
sion for mortality after ART initiation. In univariate ana-
lysis, hemoglobin, log10 plasma ANG-2, log10 ANG-2:
ANG-1 ratio, and log10 soluble ICAM-1 were associated
with mortality at p < 0.10. No predictors remained sig-
nificant in a model including hemoglobin, log10 plasma
Figure 1 Log10-transformed Plasma Angiopoietin-1 (A),
Angiopoietin-2 (B), and Angiopoietin-2:Angiopoietin-1 Ratio (C)
after ART Initiation. Solid circles represent individual data points.
Horizontal lines through the data points represent group median
values. P values indicate pairwise comparisons between time-points
(baseline, month 6, and month 12 after ART initiation) based on
Wilcoxon matched-pairs signed rank tests, as presented in Table 1.
There were 95 paired samples for the baseline to month 6
comparison, and 89 paired samples for the baseline to month 12
comparison. ANG-1 = angiopoietin-1, ANG-2 = angiopoietin-2.
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Table 2 Correlates of change in log10 angiopoietin-1 level after ART initiation, GEE analysis
Bivariable model a Multivariable model b
Mean change, ( 95% CI) P value Mean change, ( 95% CI) P value
Baseline predictor
Hormonal status
No exogenous hormones Reference Reference
Oral contraceptive pills −0.049 (−0.172 to 0.073) 0.43 −0.154 (−0.330 to 0.022) 0.09
DMPA 0.059 (−0.003 to 0.121) 0.06 0.028 (−0.055 to 0.110) 0.51
Norplant 0.013 (−0.061 to 0.086) 0.74 0.039 (−0.052 to 0.131) 0.40
Nutritional status
Adequate nutrition Reference Reference
Mild to moderate malnutrition −0.089 (−0.198 to 0.020) 0.11 −0.083 (−0.192 to 0.026) 0.14
Severe malnutrition −0.191 (−0.236 to −0.147) <0.001 −0.212 (−0.286 to −0.137) <0.001
Karnofsky Performance Score
Asymptomatic or mild symptoms (90–100) Reference Reference
Moderate symptoms (80) 0.031 (−0.046 to 0.109) 0.43 0.039 (−0.041 to 0.119) 0.34
Unable to work (<80) 0.100 (0.030 to 0.170) 0.005 0.091 (0.015 to 0.166) 0.02
WHO Stage
Stage I Reference
Stage II −0.016 (−0.103 to 0.071) 0.72
Stage III −0.070 (−0.138 to −0.002) 0.04
Stage IV −0.092 (−0.194 to 0.009) 0.08
CD4 Category (cells/μL)
<200 Reference
200–350 0 (−0.088 to 0.087) 0.98
>350 −0.038 (−0.070 to −0.007) 0.02
Time-dependent predictor
Change in Log10 Angiopoietin-2 (ng/mL) 0.037 (−0.016 to 0.091) 0.17 0.053 (0.018 to 0.087) 0.003
Suppressed Plasma HIV-1 RNA 0.042 (−0.015 to 0.098) 0.15 0.055 (0 to 0.109) 0.05
Hormonal status
No exogenous hormones Reference Reference
Oral contraceptive pills −0.013 (−0.200 to 0.173) 0.89 0.044 (−0.183 to 0.271) 0.70
DMPA 0.053 (−0.011 to 0.117) 0.10 0.020 (−0.065 to 0.105) 0.65
Norplant 0.024 (−0.068 to 0.115) 0.61 —
Pregnant −0.200 (−0.371 to −0.029) 0.02 −0.275 (−0.469 to −0.082) 0.005
Nutritional status
Adequate nutrition Reference
Mild to moderate malnutrition 0.044 (−0.151 to 0.238) 0.63
Severe malnutrition −0.093 (−0.124 to −0.062) <0.001
CI Confidence interval, GEE generalized estimating equations.
a Adjusted for baseline log10 angiopoietin-1 level (ng/mL).
b Adjusted for baseline log10 angiopoietin-1 level (ng/mL) and other covariates presented. Change in ANG-2 and virologic suppression were included a priori in
multivariable modeling.
N.B. Variables not significant at p < 0.10 in bivariate analysis are not included in the table, including baseline ANG-2, baseline plasma HIV-1 RNA, baseline age,
baseline tuberculosis, tobacco use, alcohol use, time-dependent ANG-2, time-dependent plasma HIV-1 RNA, change in plasma HIV-1 RNA, time-dependent
Karnofsky Performance Score, time-dependent tuberculosis, and time-dependent CD4 category. Data from one visit with an outlier value for log10 angiopoietin-1
have been excluded, as described in the text.
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Table 3 Correlates of change in Log10-transformed angiopoietin-2 level after ART initiation, GEE analysis
Bivariable model a Multivariable model 1 b Multivariable model 2 c
Mean change
(95% CI) P value
Mean change





No exogenous hormones Reference Reference Reference
Oral contraceptive pills 0.474 (0.175 to 0.772) 0.002 0.661 (0.393 to 0.929) <0.001 0.660 (0.397 to 0.922) <0.001
DMPA 0.166 (−0.080 to 0.411) 0.19 0.078 (−0.152 to 0.307) 0.51 0.082 (−0.144 to 0.308) 0.48
Norplant −0.290 (−0.960 to
0.380)
0.40 −0.389 (−1.012 to
0.235)





Mild to moderate malnutrition −0.278 (−0.670 to
0.113)
0.16




Stage I Reference Reference Reference
Stage II 0.031 (−0.344 to 0.407) 0.87 −0.088 (−0.439 to
0.263)
0.62 −0.061 (−0.413 to
0.291)
0.73
Stage III −0.151 (−0.466 to
0.163)
0.35 −0.307 (−0.621 to
0.006)
0.06 −0.291 (−0.604 to
0.022)
0.07
Stage IV −0.546 (−0.998 to
−0.093)
.02 −0.492 (−0.946 to
−0.039)





200–350 −0.260 (−0.515 to
−0.006)
0.04
>350 0.060 (−0.081 to 0.202) 0.40
Time-dependent predictor
Log10 Angiopoietin-1 (ng/mL) 0.683 (0.144 to 1.222) 0.01
Change in Log10 ANG-1 (ng/mL) 0.709 (0.134 to 1.284) 0.02 0.953 (0.536 to 1.370) <0.001 0.944 (0.534 to 1.354) <0.001
Suppressed Plasma HIV-1 RNA −0.158 (−0.381 to
0.064)
0.16 −0.182 (−0.378 to
0.014)
0.07
Log10 Plasma HIV-1 RNA (copies/mL) 0.142 (0.050 to 0.235) 0.003 0.128 (0.029 to 0.228) 0.012
Change in Log10 Plasma HIV-1 RNA (copies/
mL)
0.102 (0.022 to 0.182) 0.01
Hormonal status
No exogenous hormones Reference Reference Reference
Oral contraceptive pills 0.367 (0.130 to 0.604) 0.002 0.019 (−0.160 to 0.199) 0.83 0.042 (−0.127 to 0.210) 0.63
DMPA 0.264 (0.021 to 0.506) 0.03 0.098 (−0.130 to 0.326) 0.40 0.123 (−0.108 to 0.353) 0.30
Norplant −0.353 (−1.090 to
0.383)
0.35 — —
Pregnant 1.152 (0.591 to 1.712) <0.001 1.302 (0.795 to 1.810) <0.001 1.299 (0.749 to 1.849) <0.001
Nutritional status
Adequate nutrition Reference Reference Reference
Mild to moderate malnutrition −0.185 (−0.583 to
0.213)
0.36 −0.325 (−0.615 to
−0.035)
0.03 −0.353 (−0.664 to
−0.042)
0.03
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ANG-2, and log10 soluble ICAM-1. Because soluble
ICAM-1 was correlated with both hemoglobin (ρ =
−0.24, p = 0.01) and plasma ANG-2 levels (ρ = 0.33,
p = 0.008) but hemoglobin and plasma ANG-2 were not
correlated (ρ = −0.02, p = 0.84), we also evaluated a
model including only hemoglobin and log10 plasma
ANG-2. In this model, mortality risk after ART initiation
was related to lower baseline hemoglobin (adjusted
relative hazard [aRH] 0.41, 95% CI 0.18–0.92 for each g/
dL) and higher baseline plasma ANG-2 (aRH 75.06, 95%
CI 1.98–2,846 for each log10 ng/mL). In a sensitivity
analysis in which women who were lost to follow-up
were assumed to have died, log10 plasma ANG-2 was
still associated with an increased risk of mortality (aHR
8.43, 95% CI 1.42–50.07), but hemoglobin was not (aHR
0.77, 95% CI 0.51–1.16).
Table 3 Correlates of change in Log10-transformed angiopoietin-2 level after ART initiation, GEE analysis (Continued)
Severe malnutrition 0.627 (0.441 to 0.813) <0.001 0.688 (0.406 to 0.970) <0.001 0.729 (0.433 to 1.015) <0.001
Current tuberculosis 0.635 (0.191 to 1.079) 0.005 0.557 (0.137 to 0.977) 0.009 0.491 (0.053 to 0.929) 0.03
CD4 Category (cells/μL)
<200 Reference
200–350 −0.266 (−0.526 to
−0.007)
0.04
>350 −0.145 (−0.435 to
0.145)
0.33
CI Confidence interval, GEE generalized estimating equations.
a Adjusted for baseline log10 angiopoietin-2 level (ng/mL).
b Adjusted for baseline log10 angiopoietin-2 level (ng/mL) and other covariates presented. Change in ANG-1 and virologic suppression were included a priori in
multivariable modeling.
c Adjusted for baseline log10 angiopoietin-2 level (ng/mL) and other covariates presented. Change in ANG-1 was included a priori and log10 plasma HIV-1 RNA was
substituted for virologic suppression in multivariable modeling.
N.B. Variables not significant at p < 0.10 in bivariate analysis are not included in the table, including baseline ANG-1, baseline plasma HIV-1 RNA, baseline age,
baseline Karnofsky Performance Score, baseline tuberculosis, tobacco use, alcohol use, and time-dependent Karnofsky Performance Score. Data from one visit with
an outlier value for log10 angiopoietin-1 have been excluded, as described in the text.
Table 4 Predictors of mortality following ART initiation
Predictor at ART initiation HR, 95% CI
P value
Model 1 adjusted




Age (years) 1.04 (0.90 − 1.21) 0.57
BMI (kg/m2) 0.94 (0.78–1.14) 0.56
Karnofsky Performance Scale
Minor symptoms (90) Reference
Moderate symptoms (80) 1.11 (0.11–10.63) 0.93
Unable to work (<80) 5.34 (0.55–51.38) 0.15
Current tuberculosis 3.01 (0.50–18.02) 0.23
WHO Stage
Stage I Reference
Stage II 0.66 (0.04–10.49) 0.77
Stage III 0.85 (0.08–9.34) 0.89
Stage IV 1.80 (0.11–28.77) 0.68
CD4 Cell count (cells/μL) 0.99 (0.97–1.01) 0.22
Log10 Plasma HIV-1 RNA (copies/mL) 3.00 (0.62–14.60) 0.17
Hemoglobin (g/dL) 0.59 (0.33–1.07) 0.08 0.51 (0.21–1.23) 0.13 0.41 (0.18–0.92) 0.03
Log10 Angiopoietin-1 (ng/mL) 0.25 (0.005–13.63) 0.50
Log10 Angiopoietin-2 (ng/mL) 18.85 (1.52–233.7) 0.02 41.31 (0.82–2,086) 0.06 75.06 (1.98–2,846) 0.02
Log10 ANG-2/ANG-1 ratio 19.99 (1.66–240.5) 0.02
Log10 s-ICAM (ng/mL) 10,062 (18.29–5,536,091) 0.004 355.8 (0.22–581,538) 0.12
Log10 E-selectin (ng/mL) 11.17 (0.18–696.4) 0.25
Log10 VCAM (ng/mL) 9.33 (0.14–644.0) 0.30
ART antiretroviral therapy, CI confidence interval, HR hazard ratio.
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Discussion
This study adds to the very limited data on angiopoietins
in HIV-1 infection and, to our knowledge, demonstrates
their clinical significance in this setting for the first time.
The women we studied had advanced HIV disease, with
high plasma HIV-1 RNA and low CD4 cell counts at
ART initiation. The majority achieved virologic suppres-
sion after ART. We found that plasma ANG-1 increased
and plasma ANG-2 decreased after ART initiation, with
a concomitant decline in the plasma ANG-2:ANG-1
ratio. These changes were accompanied by consistent
decreases in soluble ICAM-1, and, less consistently,
reductions in plasma levels of soluble VCAM-1 and
E-selectin. Such decreases in plasma levels of soluble ad-
hesion molecules are in accordance with the published
literature [10,11].
Plasma ANG-1 levels were lower in women with se-
vere malnutrition at baseline and pregnancy during
follow-up. Higher plasma ANG-2 levels were associated
with oral contraceptive pill use at baseline and with
pregnancy, severe malnutrition, and tuberculosis during
follow-up. In addition, higher plasma ANG-2 levels after
ART initiation were associated with higher plasma HIV-
1 RNA. Baseline ANG-2 levels and ANG-2:ANG-1 ratio
values were higher in women who died after ART initi-
ation. As previously demonstrated in another cohort
[12], baseline soluble ICAM-1 levels were associated
with an increased risk of mortality over follow-up. We
found that soluble ICAM-1 levels correlated significantly
with both plasma ANG-2 and hemoglobin, and that a
model including only plasma ANG-2 and hemoglobin fit
our data better than one including all three predictors.
Peripheral blood (plasma and serum) ANG-2 levels,
which are indicative of an activated endothelium, are
often below the limit of assay detection in healthy per-
sons. In contrast, 84% of participants in this study had
detectable plasma ANG-2 levels at baseline. While
plasma ANG-2 levels were linked to opportunistic illness
(i.e., tuberculosis and very low BMI) in this population,
the decrease in the plasma ANG-2:ANG-1 ratio after
ART initiation and the association between plasma
ANG-2 levels and HIV-1 RNA levels after ART suggest
that HIV-1 itself can drive endothelial activation. In sup-
port of our hypothesis that ART would not completely
normalize endothelial activation, plasma ANG-2 was de-
tectable in 69% of participants at month 12. These find-
ings, as well as the association of higher plasma ANG-2
levels with increased mortality, require confirmation in
other study populations. In addition, because our study
was not aimed at elucidating how angiopoietin levels are
regulated in HIV-1 infection, further work is needed to
demonstrate whether plasma ANG-2 is increased pri-
marily by locally induced cytokines, by a direct effect of
HIV-1 on endothelial cells [25], or by other factors. Of
note, circulating monocytes are a site of ANG-2 produc-
tion [26] and are activated in HIV-1 infection. Increased
levels of soluble CD14, which is expressed mainly by
macrophages and may be a consequence of microbial
translocation [27], have also been related to mortality in
HIV-1-infected patients [28]. Because inflammation
from opportunistic infections may also increase plasma
HIV-1 RNA levels, it is possible that the association we
detected between HIV-1 RNA and endothelial activation
was due primarily to immune reconstitution and undiag-
nosed opportunistic infections in this population.
We detected significant associations between angio-
poietin levels and hormonal status, with higher plasma
ANG-2 levels in pregnancy and with the use of oral
contraceptive pills. ANG-2 is known to play an essential
role in embryonic angiogenesis and placental develop-
ment [29], and therefore its association with pregnancy
is not surprising. We could find no previous report of an
association between angiopoietin levels and hormonal
contraception. However, estrogen stimulates ANG-2
mRNA expression and inhibits ANG-1 expression in
non-reproductive organs [30], and plasma ANG-2 levels
are higher in non-pregnant women than in men [31].
We also found a relationship between angiopoietin levels
and severe malnutrition as defined by BMI < 16. Al-
though there is evidence that poor dietary choline intake
increases ANG-2 in an animal model [32], we could
identify no studies investigating the effect of nutritional
status on plasma angiopoietin levels in adults. Future
studies of angiopoietin biology in female participants
and in populations in which malnutrition is prevalent
should consider adjustments for these factors.
Because endothelial cells are involved in many aspects
of vascular biology, including barrier function, immune
surveillance, blood clotting, and atherosclerosis, ongoing
endothelial activation as manifested by persistent eleva-
tions in plasma ANG-2 may predispose to a wide array
of adverse outcomes. Since the SMART (Strategies for
Management of Antiretroviral Therapy) trial demon-
strated a high rate of mortality in untreated HIV-1 infec-
tion due to non-AIDS events, numerous biomarkers of
adverse outcomes have been identified [27]. In addition,
the question of whether adjunct treatments used in
combination with ART can reduce HIV-1-related inflam-
mation has been posed [3,33]. Although anti-inflamma-
tory drugs have some effect on inflammatory biomarkers
[34], interventions that target inflammatory biomarkers
in HIV-1 infection have largely been unsuccessful to date
[35-37]. ANG-2 is an important mediator of endothelial
activation that has been linked to reduced endothelial
nitric oxide availability and vascular dysfunction [38,39],
and may be a point of intervention to modulate host re-
sponse. If further research confirms our findings in this
study, investigation of whether HIV-1-related endothelial
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activation predicts vascular dysfunction and end-organ
disease may lead to the development of new intervention
strategies. Therapeutic agents targeting the angiopoietin/
Tie-2 system, ANG-2 antagonists, and agents that in-
crease endothelial nitric oxide are all in development
[13,40], and may have potential applications in HIV-1
-infected persons with elevated plasma ANG-2 levels.
An important strength of this study is its prospective
design, in which participants were used as their own
controls. However, this study had several limitations.
First, a limited quantity of stored heparinized plasma
was available for this study, and all potential biomarkers
of interest could not be tested. Second, our limited sam-
ple size and follow-up reduced power and precision for
our survival analysis. Nevertheless, we detected a signifi-
cant association between plasma ANG-2 levels and mor-
tality. Third, we could not establish causes of death and
were unable to control for specific opportunistic infec-
tions other than tuberculosis, due to limited diagnostic
capability at the field site. Fourth, outcomes for the
women who were lost to follow-up are unknown. Be-
cause loss to follow-up may have been associated with
mortality, we conducted a sensitivity analysis and found
that plasma ANG-2 levels remained associated with
mortality when these women were assumed to have died.
Fifth, no clinically relevant cut-points have been
established for endothelial activation biomarkers, and as-
says are not standardized between laboratories, making
direct comparisons between studies difficult to interpret.
Finally, our analysis was restricted to a cohort of Kenyan
women with advanced HIV-1 disease and opportunistic
infections. Although many adult patients in Africa
present with a similar degree of immunosuppression,
our findings cannot be generalized to men, to adults in
other settings, or to adults with less advanced HIV-1 dis-
ease. Additional research will be needed to determine if
angiopoietin levels are influenced by HIV-1 acquisition
and if biomarkers of endothelial activation remain asso-
ciated with adverse outcomes among HIV-1-infected pa-
tients taking long-term suppressive ART.
Conclusions
In conclusion, endothelial activation was present in
women with advanced HIV infection, and improved after
ART initiation, with an increase in plasma ANG-1 levels
and a decrease in plasma ANG-2 levels. Higher plasma
ANG-2 levels were associated with higher plasma HIV-1
RNA after treatment initiation. Angiopoietin dysregulation
was associated with pregnancy, malnutrition, and tubercu-
losis, and may also have been related to undiagnosed
immune reconstitution inflammatory syndrome or oppor-
tunistic infections. Baseline plasma ANG-2 levels were
higher among women who died after ART initiation. Our
results add significantly to the limited data on angiopoietin
levels in HIV-1-infected patients, and suggest that further
investigation into HIV-1-related endothelial activation is
warranted, including research on whether plasma ANG-1
and ANG-2 may be useful biomarkers for HIV-1-related
morbidity and mortality.
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